我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

玉屏风散加味方对肺气虚寒型变应性鼻炎患者的临床疗效 及IL-17A、TGF-β1表达的影响*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2018年04期
页码:
41-46
栏目:
临床研究
出版日期:
2019-03-25

文章信息/Info

Title:
Effect of Modified Yupingfeng San of Lung Deficiency-cold Type AR Patients with the Clinical Efficacy and IL-17A, TGF-β1 Expression
文章编号:
1000 - 2723(2018)04 - 0041 - 06
作者:
张丽娟1李得堂2△庞志宇2刘媛3钟如帆3
(1. 广州中医药大学附属中山医院,广东 中山 528400;2. 广州中医药大学第一附属医院,广东 广州 510405; 3. 广州中医药大学,广东 广州 510405)
Author(s):
ZHANG Lijuan1 LI Detang2 PAN Zhiyu2 LIU Yuan3 ZHONG Rufan3
(1. Zhongshan Hospital Affiliated To Guangzhou University of Chinese Medicine, ZhongShan 528400, China; 2. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China; 3. Guangzhou University of Chinese Medicine, Gua
关键词:
玉屏风散加味 Thl7/Treg细胞 不同分类与分度
Keywords:
modified Yupingfeng San Thl7/Treg cell different classifications and grades
分类号:
R276.1
DOI:
10.19288/j.cnki.issn.1000-2723.2018.04.009
文献标识码:
A
摘要:
目的探讨玉屏风散加味方对肺气虚寒型变应性鼻炎(allergic rhinitis,AR)患者的疗效,及外周血Th17/Treg细胞中特征因子IL-17A、TGF-β1表达的影响。方法选取肺气虚寒型AR患者19例,健康志愿者10例作对照,肺气虚寒型AR患者组进行分类及分度为4组:轻度间歇性、中-重度间歇性、轻度持续性及中-重度持续性,玉屏风散加味方治疗14 d,进行治疗前后量表评分,评价其临床疗效,及ELISA法检测治疗前后各组血清IL-17A、TGF-β1的表达。结果玉屏风散加味方治疗后,VAS、TNSS、TNNSS及RQLQ量表评分均显著低于治疗前(**P<0.01)。19例肺气虚寒型AR患者IL-17A及TGF-β1表达显著高于对照组(**P<0.01),不同分类与分度的肺气虚寒型AR患者,中-重度间歇性、轻度持续性及中-重度持续性AR组IL-17A及TGF-β1表达显著高于对照组(**P<0.01,*P<0.05),轻度间歇性AR组IL-17A表达明显高于对照组(*P<0.05),而轻度间歇性AR组TGF-β1表达与对照组无差别(P>0.05)。中-重度间歇性、轻度持续性及中-重度持续性AR组IL-17A及TGF-β1表达明显高于轻度间歇性AR(*P<0.05)。治疗后,IL-17A、TGF-β1表达均有下降,治疗组IL-17A及TGF-β1表达明显低于治疗前的AR组(*P<0.05,**P<0.01),具有统计学差异。结论肺气虚寒型AR患者,玉屏风散加味方治疗后,粘膜水肿、炎症和鼻痒、喷嚏、清水样鼻涕的症状明显改善,量表评分值显著降低,Th17/Treg免疫失衡有所改善,玉屏风散加味方对肺气虚寒型AR患者有确切的临床疗效及调节Th17/Treg免疫失衡的作用。
Abstract:
Objective To investigate the therapeutic effect of modified Yupingfeng San on Lung deficiency-cold type AR patients, and the influence of peripheral blood Th17/Treg cells characteristic factor IL-17A, TGF-β1 expression. Methods The selection of the treatment of 19 cases of lung deficiency-cold type AR patients, 10 healthy volunteers as control group, of patients with AR deficiency type classification and dividing into 4 groups: Mild intermittent AR、 Moderate to severe intermittent AR、 Mild persistent AR and Moderate to severe persistent AR, modified Yupingfeng San for the treatment of 14d, treatment before and after the score and to evaluate its clinical efficacy, the expression of serum IL-17A, TGF-β1 and ELISA were detected before and after treatment. Results The scores of VAS, TNSS, TNNSS and RQLQ were significantly lower than those before treatment after the treatment of modified Yupingfeng San(**P<0.01). 19 cases of lung deficiency-cold type AR patients IL-17A and TGF-β1 expression was significantly higher than the control group(**P<0.01), different classifications and grades of lung deficiency-cold type AR patients, moderate to severe intermittent, mild persistent and moderate severe persistent AR group IL-17A and TGF-β1 expression was significantly higher than the control group(**P<0.01, *P<0.05), mild intermittent group IL-17A expression was significantly higher than the control group(*P<0.05), and mild intermittent AR group TGF-β1 expression no difference the control group(*P>0.05). The expression of IL-17A and TGF-β1 in moderate to severe intermittent, mild persistence and moderate to severe persistent AR group was significantly higher than that of mild intermittent AR(*P<0.05). After treatment, the expression of IL-17A and TGF-β1 decreased. The expression of IL-17A and TGF-β1 in the treatment group was significantly lower than that in the AR group before treatment, with statistical difference(**P<0.01, *P<0.05). Conclusion Patients with lung deficiency-cold type AR, modified Yupingfeng San prescription treatment, mucosal edema, inflammation and nasal itching, sneezing, rhinorrhea symptoms improved, gauge score was significantly reduced, the immune imbalance of Th17/Treg improved effect of modified Yupingfeng San of lung deficiency-cold type AR patients have clinical curative effect and regulation the immune imbalance of Th17/Treg.

参考文献/References


[1] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组,中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志,2016,51(1):6-24.
[2] 韩德民. 过敏性鼻炎[M]. 北京:人民卫生出版社,2014. 113-150.
[3] YILMAZ O, BAKIRTAS A, ERTOY K H, et al. Allergic rhinitis may impact the recovery of pulmonary function tests after moderate/severe asthma exacerbation in children[J]. Allergy,2014,69(5):652-657.
[4] WU Y B, JAMES L K, VANDER HEIDEN J A, et al. Influence of seasonal exposure to grass pollen on local and peripheral blood IgE repertoires in patients with allergic rhinitis[J]. Journal of Allergy and Clinical Immunology,2014,134(3):604-612.
[5] DURHAM S R, CRETICOS P S, NELSON H S, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis:Pooled analyses[J]. Journal of Allergy and Clinical Immunology,2016,138(4):1081-1088.
[6] D’AMATO G, VITALE C, DE MARTINO A, et al. Effects on asthma and respiratory allergy of climate change and air pollution[J]. Multidiscip Respir Med,2015,10:39.
[7] HENDAUS M, JOMHA F, EHLAYEL M. Allergic diseases among children:nutritional prevention and intervention[J]. Therapeu Clin Risk Management,2016,12(1):361-372.
[8] 章如新. 变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报,2016,30(4):3-6.
[9] XU G, MOU Z, JIANG H, et al. A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis[J]. Laryngoscope,2007,117(5):876-880.
[10] YEH H, MOORE D J, MARKMANN J F, et al. Mechanisms of regulatory T cell counter regulation by innate immunity[J]. Transplant Rev(Orlando),2013,27(2):61-64.
[11] 干祖望,干千. 干祖望经验集[M]. 北京:人民卫生出版社,2002:162-168.
[12] 丁琦,袁卫玲,刘华. 从寒论治过敏性鼻炎的理论探讨[J]. 辽宁中医杂志,2016(5):942-943.
[13] 陈宇,唐月英,周美玲,等. 益气固表法治疗肺气虚型变应性鼻炎的研究[J]. 中华中医药杂志,2015(9):3337-3340.
[14] 谢慧. 变应性鼻炎的中医治疗[J]. 山东大学耳鼻喉眼学报,2016,30(4):22-25.
[15] 刘亚雄. 从《内经》“鼽”谈对过敏性鼻炎的认识[J]. 云南中医中药杂志,2016(11):114-115.
[16] 袁卫玲,刘丹,李媛媛,等. 过敏性鼻炎季节易感性发病机制的理论探讨[J]. 中华中医药杂志,2016,31(1):78-79.
[17] BOUSQUET J, Khahaev N, Cruz A A, et al. Allergic rhinitis and its impact on asthma(ARIA):2008 update(in collaboration with the World Health Organization,GA2 LEN and AllerGen)[S]. Allergy,2008,63(Suppl 86):8-160.
[18] BOUSQUET J, SCHUNEMANN H J, SAMOLINSKI B, et al. Allergic rhinitis and its impact on asthma (ARIA):achievements in 10 years and future needs[J]. J Allergy ClinImmunol,2012,130(5):1049-1062.
[19] VUURMAN E F, VUURMAN L L, LUTGENS I, et al. Allergic rhinitis is a risk factor for traffic safety[J]. Allergy,2014,69(7):906-912.
[20] ZUBERBIER T, LOTVALL J, SIMOENS S, et al. Economic burden of inadequate management of allergic diseases in the European Union:a GA(2)LEN review[J]. Allergy,2014,69(10):1275-1279.
[21] BROZEK J L, BOUSQUET J, AGACHE I, et al. Allergic Rhinitis and its Impact on Asthma(ARIA)guidelines-2016 revision[J]. J Allergy Clin Immunol,2017,140(4):950-958.

备注/Memo

备注/Memo:
收稿日期: 2018 - 07- 27
*基金项目: 广东省自然科学基金项目(2017A030313626);中山市科技计划项目(2015B1052)
第一作者简介: 张丽娟(1982-),女,硕士,主治中医师,研究方向:中医耳鼻咽喉疾病的临床与基础研究。
△通信作者: 李得堂,E-mail:lidetang2002@163.com
更新日期/Last Update: 2018-10-30